SLC5A2 and chronic kidney disease: This could limit the potential of this group to benefit from interventions, such as RAS inhibitors and SGLT2 inhibitors, given that their risk of CVD and progressive CKD will be comparatively lower than other groups with high CKD prevalence, such as those with diabetes.